HPS Pharmacies wish to give notice that Haleon Australia, in consultation with the Therapeutic Goods Administration (TGA), has issued a product defect correction and recall for Panadol® Children 1 Month – 1 Year, as follows:
Panadol Children 1 Month – 1 Year
Paracetamol 100 mg/mL
ARTG 83363
The following batches are affected by this notice:
- DR562 (Exp 30/04/2024)
- DR563 (Exp 30/04/2024)
- DT528 (Exp 30/04/2024)
- DS947 (Exp 31/07/2024)
- DS956 (Exp 31/08/2024)
- DT334 (Exp 30/09/2024)
- DT469 (Exp 30/09/2024)
- DT762 (Exp 31/10/2024)
- DT912 (Exp 31/10/2024)
- DU128 (Exp 30/11/2024)
- DT913 (Exp 31/10/2024)
- DW301 (Exp 28/02/2025)
- DW507 (Exp 28/02/2025)
- DW487 (Exp 28/02/2025)
This defect correction was initiated as the supplied dosing syringe may be stiff and difficult to use. This may make it difficult to control the delivery of the medicine and may pose a risk of choking. There are no safety or quality problems with the liquid medicine itself.
Please inspect your stock and quarantine all affected products. If HPS Pharmacies provide imprest management services to your facility, an HPS representative will inspect all stock stored in the designated imprest areas at the earliest opportunity. All affected products will be quarantined for return to the supplier, and HPS Pharmacies will arrange for replacement stock as soon as possible. An HPS Pharmacies staff member will contact senior medical and nursing staff if there is an immediate impact to your facility.
Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Haleon on 1800 028 533 or your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates